Misc. news stories

New research published in Scientific Reports found that people who microdose psychedelics displayed greater improvements in mental health and mood over the span of 1 month compared to non-microdosers.

Scientists have taken an important first step into studying the effects of the psychedelic drug psilocybin — the active substance in “magic” mushrooms — at a cellular and genetic level. Their findings, published in Scientific Reports, indicate that a single dose of psilocybin produces a long-lasting antidepressant-like effect in flies.

Scientists probe the link between serotonin and cannabinoid signaling.

Image from: Apollo (Wiki Commons)

In the quest to discover the most effective psychedelic medicines for treating mental health conditions, some have pointed to DMT as a potential tool for treating depression. Now, a new study published in Nature lends credence to using DMT as a rapid-acting antidepressant.

Psilocybin is associated with general long-lasting positive psychological effects in healthy individuals as well. New research published in Frontiers in Pharmacology indeed found that psilocybin-induced psychedelic experiences are associated with long-lasting positive effects.

Shrooms, Alice, tweezes, mushies, hongos, pizza toppings, magic mushrooms — everyday lingo for psychedelic mushrooms seems to grow with each generation. Yet leading mycologist Paul Stamets believes it’s time for fans of psilocybin mushrooms to leave such childish slang behind.

“In the history of our species, a number of civilians have practiced or allowed human sacrifice including the sacrifice of children,” he said.

“The Carthaginians, the Mesopotamians, the Incas, the Aztecs,” he listed.

“Will we be recorded as such as society that accepts the sacrifice of innocence?”

Image from Wiki Commons

The former chief of the Australian defence force, Chris Barrie, is campaigning to remove barriers stymying doctors from using MDMA to treat veterans suffering post-traumatic stress disorder and depression, saying he hopes “common sense is going to prevail”.

Up to 30% of people with depression don’t respond to treatment with antidepressants…So there is an urgent need to expand the repertoire of drugs available to people with depression.

A comprehensive assessment of the benefits of medical cannabis for cancer-related pain found that for most oncology patients, pain measures improved significantly, other cancer-related symptoms also decreased, the consumption of painkillers was reduced, and the side effects were minimal.

At the American Psychiatric Association (APA) 2022 Annual Meeting that began on May 21 in New Orleans, Louisiana, COMPASS Pathways unveiled the “largest randomized, controlled, double-blind study of psilocybin therapy ever completed,” according to a May 24 press release, and the data shows “significant” improvements to treatment-resistant depression (TRD) symptoms.

Two recent studies, published in The New England Journal of Medicine and Nature Medicine, have shed some light on this mysterious process.

Startup Clerkenwell Health hopes to help make UK a world leader in psychedelics research.

Psilocybin-assisted therapy has shown promise as a treatment for depression. New research published in Cannabis finds that cannabis users expected that cannabis-assisted therapy could produce similar subjective experiences and have similar therapeutic benefits for the treatment of depression as psilocybin-assisted treatment.